Provided by Tiger Trade Technology Pte. Ltd.

Pacira Pharmaceuticals

24.86
+0.19000.77%
Post-market: 24.860.00000.00%17:31 EDT
Volume:336.66K
Turnover:8.35M
Market Cap:990.97M
PE:70.67
High:25.04
Open:24.60
Low:24.49
Close:24.67
52wk High:27.66
52wk Low:18.80
Shares:39.86M
Float Shares:36.37M
Volume Ratio:0.73
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3518
EPS(LYR):0.1578
ROE:2.05%
ROA:1.48%
PB:1.47
PE(LYR):157.51

Loading ...

Pacira BioSciences to join RBC Capital Markets healthcare conference fireside chat

Reuters
·
May 13

BRIEF-Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees

Reuters
·
May 13

Pacira urges vote for board slate as activist DOMA pushes CEO ouster, sale process

Reuters
·
May 13

Pacira Biosciences Sends Letter to Stockholders Reiterating Superior Qualifications of Its Board Nominees

THOMSON REUTERS
·
May 13

Pacira grants inducement equity awards to new hires, options priced at $24.69

Reuters
·
May 08

Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 08

Pacira urges vote for board slate, rejects activist DOMA push for CEO change, sale talks

Reuters
·
May 06

Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast

Stock Track
·
May 01

Analysts’ Top Healthcare Picks: Pacira Pharmaceuticals (PCRX), Cadrenal Therapeutics, Inc. (CVKD)

TIPRANKS
·
May 01

RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating

MT Newswires Live
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.41% Intraday on Strong Q1 Earnings Beat, Revenue Growth and Maintained Buy Rating

Stock Track
·
May 01

Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating

Stock Track
·
May 01

Pacira BioSciences Is Maintained at Buy by Needham

Dow Jones
·
May 01

Pacira Q1 revenue beats estimates, co raises 2026 outlook

Reuters
·
May 01

Pacira reports Q1 EPS 60c, consensus 56c

TIPRANKS
·
May 01

Pacira Q1 FY26 net income drops 39% to USD 2.9 million; revenue rises 5% to USD 177 million

Reuters
·
May 01

BRIEF-Pacira Biosciences Q1 Revenue USD 177 Million Vs. IBES Estimate USD 173.3 Million

Reuters
·
May 01

Pacira BioSciences Q1 Adj. EPS $0.60 Beats $0.56 Estimate, Sales $177.376M Beat $173.325M Estimate

Benzinga Earnings
·
May 01

Pacira Biosciences Inc - Reiterates 2026 Guidance

THOMSON REUTERS
·
May 01

Pacira Biosciences Q1 Cash & Investments USD 202.2 Million

THOMSON REUTERS
·
May 01